Table 3.
Comparison of clinical data between the CNV status among the subjects, n (%) or medians (IQRs).
| Variables | Case (n = 303) | Control (n = 303) | P-value* | |||||
|---|---|---|---|---|---|---|---|---|
| Losses (n = 25) |
Neutral (n = 194) |
Gains (n = 84) |
P-value* | Losses (n = 12) |
Neutral (n = 215) |
Gains (n = 76) |
||
| ALT (IU/L) | 28.00 (17.50, 42.50) | 27.00 (21.00, 38.25) | 31.00 (23.00, 42.75) | 0.17 | 20.50 (16.25, 33.75) | 19.00 (14.00, 26.00) | 18.50 (15.00, 26.75) | 0.38 |
| AST (IU/L) | 23.00 (18.00, 31.50) | 22.00 (19.00, 28.00) | 24.00 (20.00, 31.00) | 0.12 | 24.50 (20.00, 30.75) | 20.00 (17.00, 24.00) | 21.00 (18.00, 27.00) | 0.06 |
| GGT (IU/L) | 27.00 (21.00, 37.00) | 30.00 (22.00, 46.00) | 34.00 (24.00, 47.75) | 0.27 | 21.50 (13.25, 28.75) | 22.00 (16.00, 32.00) | 24 (17.00, 33.50) | 0.70 |
| TC (mmol/L) | 4.96 (4.30, 5.63) | 5.09 (4.50, 5.88) | 5.17 (4.60, 5.73) | 0.72 | 4.68 (4.21, 5.12) | 4.94 (4.49, 5.43) | 4.92 (4.37, 5.44) | 0.37 |
| TG (mmol/L) | 1.48 (1.29, 2.10) | 1.82 (1.29, 2.69) | 1.76 (1.20, 2.48) | 0.35 | 1.15 (0.81, 1.51) | 1.12 (0.88, 1.48) | 1.12 (0.86, 1.44) | 0.92 |
| HDL-C (mmol/L) | 1.17 (0.97, 1.30) | 1.21 (1.04, 1.37) | 1.19 (0.98, 1.39) | 0.58 | 1.33 (1.11, 1.51) | 1.35 (1.20, 1.48) | 1.37 (1.20, 1.48) | 0.74 |
| LDL-C (mmol/L) | 3.09 (2.52, 3.75) | 3.12 (2.54, 3.80) | 3.14 (2.63, 3.65) | 0.83 | 2.75 (2.40, 3.32) | 3.03 (2.61, 3.49) | 2.99 (2.65, 3.57) | 0.40 |
| CES1 (ng/ml) | 17.95 (11.91, 27.97) | 13.25 (10.61, 18.65) | 13.25 (10.42, 17.68) | 0.07 | 12.88 (8.28, 17.03) | 13.13 (10.50, 21.41) | 13.13 (10.73, 20.99) | 0.54 |
CNVs, copy number variation; IQR, interquartile range; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CES1, carboxylesterase 1.
*P-values were calculated by using the Chi-square test for categorical variables and Kruskal Wallis test for continues variables.